References
- James C, Ugo V, Le Couedic J P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148
- Pikman Y, Lee B H, Mercher T, McDowell E, Ebert B L, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: E270
- Pardanani A D, Levine R L, Lasho T, Pikman Y, Mesa R A, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, DOI 101182/blood-2006-04-018879
- Frantsve J, Schwaller J, Sternberg D W, Kutok J, Gilliland D G. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol 2001; 21: 3547–3557
- Kile B T, Alexander W S. The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci 2001; 58: 1627–1635
- Marine J C, Topham D J, McKay C, Wang D, Parganas E, Stravopodis D, et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 1999; 98: 609–616
- Marine J C, McKay C, Wang D, Topham D J, Parganas E, Nakajima H, et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 1999; 98: 617–627
- Sarna M K, Ingley E, Busfield S J, Cull V S, Lepere W, McCarthy D J, et al. Differential regulation of SOCS genes in normal and transformed erythroid cells. Oncogene 2003; 22: 3221–3230
- Baker A F, Bellamy W, Tate W R, Bair W B, 3rd, Heaton R, List A F. Suppressor of cytokine signaling-3 is overexpressed in erythroid precursors of myelodysplastic syndrome. Leukemia 2006; 20: 1620–1621
- Usenko T, Eskinazi D, Correa P N, Amato D, Ben-David Y, Axelrad A A. Overexpression of SOCS-2 and SOCS-3 genes reverses erythroid overgrowth and IGF-I hypersensitivity of primary Polycythemia vera (PV) cells. Leuk Lymphoma 2006; 48: 134–146
- Favre H, Benhamou A, Finidori J, Kelly P A, Edery M. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett 1999; 453: 63–66
- Galm O, Yoshikawa H, Esteller M, Osieka R, Herman J G. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003; 101: 2784–2788
- Kralovics R, Teo S S, Li S, Theocharides A, Buser A S, Tichelli A, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108: 1377–1380